Biocon And Viatris Ready To Launch EU Bevacizumab
Biocon Biologics Announces Formal EU Approval For Abevmy Biosimilar
Executive Summary
Viatris and Biocon Biologics are now in a position to enter the European market for biosimilar bevacizumab, after the European Commission formally approved the pair’s Abevmy rival to Avastin.
You may also be interested in...
Celltrion Gets Ready To Face The Competition After European Bevacizumab Nod
Celltrion has received a positive opinion from the EMA’s CHMP for its Vegzelma bevacizumab biosimilar rival to Avastin, setting up the Korean firm to enter a competitive European market that already includes several bevacizumab biosimilars.
Viatris And Biocon Launch Bevacizumab Biosimilar In Canada
Viatris and Biocon have introduced their Abevmy biosimilar bevacizumab version of Avastin in Canada. Marking the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in Canada, the product will face multiple other approved bevacizumab rivals in the market.
Biocon Pays $3.3bn For Viatris Biosimilars Business
Biocon Biologics will pay up to $3.3bn to acquire the global biosimilars business of Viatris, in a long-rumored deal that will create a vertically-integrated biosimilars giant with annual sales approaching $1bn.